Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer

Cheng Zhang(Army Medical University), Lin Shen(Hangzhou Normal University)

Cancer Medicine

June 26, 2019

10.1002/cam4.2360

Cited by 318

Related Papers

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

|Nature|2021|687

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

|Annals of Oncology|2019|475

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

|The Lancet|2023|461

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

|The Lancet Oncology|2017|291

Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial

|Gut|2018|137